Fate Therapeutics Taps Bob Valamehr to Be CEO

Dow Jones11-29
 

By Adriano Marchese

 

Fate Therapeutics has appointed Bob Valamehr to succeed Scott Wolchko as chief executive, effective a Jan. 1.

The clinical-stage biopharmaceutical company on Friday said that Valamehr has headed the development of its induced pluripotent stem cell platform, and led to 13 investigational new drug applications, covering the treatment of hematological malignancies, solid tumors and autoimmune disorders.

He is set to take over the day after Wolchko's effective retirement date of Dec. 31. Wolchko has led the San Diego-based company since 2015, and will continue to act as a strategic adviser to the company, Fate Therapeutics said.

 

Write to Adriano Marchese at adriano.marchese@wsj.com

 

(END) Dow Jones Newswires

November 29, 2024 13:38 ET (18:38 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment